The trials involve an immune system stimulant known as recombinant human interleukin-4, or new drugs known as ifosfamide, navelbine or taxol.
Lung cancer is the leading cancer killer in the United States.
They appear to be at least as effective as the best standard therapies, and their side effects are often much less severe. The result is often a better response and less discomfort for the patient, less nausea, diarrhea, weakness and other complaints associated with more traditional chemotherapy. While these drugs have shown promise in earlier studies, they also have the potential to cause serious side effects. Participants will not be charged for the medications, but will be charged for other costs associated with the study. All rights reserved.